COMP <GO>
TCMD vs ABBV // OPERATING MARGIN
Tactile Systems Technology Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: TCMD 7
— ABBV 6
▲ OPERATING MARGIN LEADER: ABBV
LAST: $24.31 (+1.67%) • MKT CAP: $550.7M
operating-margins
8.90%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
operating-margins
24.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TCMD VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TCMD | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 75.90% | 70.20% | +5.70 | TCMD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.10% | 29.00% | -11.90 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 14.9x | 33.3x | -18.40 | TCMD | /valuation <GO> |
| Free Cash Flow Yield | 7.34% | 3.47% | +3.87 | TCMD | /fcf-yield <GO> |
| Operating Margin ACTIVE | 8.90% | 24.60% | -15.70 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 5.80% | 6.90% | -1.10 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 12.50% | 8.60% | +3.90 | TCMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.38 | 5.33 | +3.05 | TCMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | TCMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.2 | 65.1 | -15.86 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.3x | 113.1x | -88.80 | TCMD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $550.7M | $513.86B | -$513.31B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TCMD REV | ABBV REV | TCMD GROSS % | ABBV GROSS % | TCMD FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $329.5M | $61.16B | 75.9% | 70.2% | $40.4M | $17.82B |
| FY 2024 | $293.0M | $56.33B | 74.0% | 70.0% | $38.3M | $17.83B |
| FY 2023 | $274.4M | $54.32B | — | — | $35.9M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TCMD // BETA —
ABBV // BETA 1.15